| 1 |
Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin,2014,64(1):9-29.
|
| 2 |
El-Serag HB. Hepatocellular carcinoma[J]. N Engl J Med,2011,365(12):1118-1127.
|
| 3 |
Guan YS, He Q, Wang MQ. Transcatheter arterial chemoembolization: history for more than 30 years[J]. ISRN Gastroenterol,2012,2012(480650.
|
| 4 |
May BJ, Murthy R, Madoff DC. What's new in transarterial therapies for hepatocellular carcinoma?[J]. Gastrointest Cancer Res,2012,5(3 Suppl 1):S14-19.
|
| 5 |
Pleguezuelo M, Marelli L, Misseri M, et al. TACE versus TAE as therapy for hepatocellular carcinoma[J]. Expert Rev Anticancer Ther,2008,8(10):1623-1641.
|
| 6 |
Wang B, Xu H, Gao ZQ, et al. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization[J]. Acta Radiol,2008,49(5):523-529.
|
| 7 |
Kim YB, Park YN, Park C. Increased proliferation activities of vascular endothelial cells and tumour cells in residual hepatocellular carcinoma following transcatheter arterial embolization[J]. Histopathology,2001,38(2):160-166.
|
| 8 |
Miyayama S, Mitsui T, Zen Y, et al. Histopathological findings after ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma[J]. Hepatol Res,2009,39(4):374-381.
|
| 9 |
Takayasu K, Muramatsu Y, Maeda T, et al. Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system: analysis of factors affecting local recurrence and survival rates[J]. AJR Am J Roentgenol,2001,176(3):681-688.
|
| 10 |
王建华，周康荣，颜志平,等.小肝癌的介入治疗研究(附42例报告)[M]. 中华放射学杂志，2000：823-826.
|
| 11 |
Takaki S, Sakaguchi H, Anai H, et al. Long-term outcome of transcatheter subsegmental and segmental arterial chemoemobolization using lipiodol for hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol,2012,35(3):544-554.
|
| 12 |
Malagari K, Pomoni M, Kelekis A, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol,2010,33(3):541-551.
|
| 13 |
Idee JM, Guiu B. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review[J]. Crit Rev Oncol Hematol,2013,88(3):530-549.
|
| 14 |
Zhou Y, Zhang X, Wu L, et al. Meta-analysis: preoperative transcatheter arterial chemoembolization does not improve prognosis of patients with resectable hepatocellular carcinoma[J]. BMC Gastroenterol,2013,13(51.
|
| 15 |
Sacco R, Bargellini I, Bertini M, et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma[J]. Journal of Vascular & Interventional Radiology,2011,22(11):1545-1552.
|
| 16 |
Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma[J]. Gastroenterology,2011,140(2):497-507 e492.
|
| 17 |
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol,2012,56(4):908-943.
|
| 18 |
Sahara S, Kawai N, Sato M, et al. Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma[J]. Cardiovascular & Interventional Radiology,2012,35(6):1363-1371.
|
| 19 |
Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies[J]. Cardiovascular & Interventional Radiology,2007,30(1):6-25.
|
| 20 |
Wang YL, Li MH, Cheng YS, et al. Influential factors and formation of extrahepatic collateral artery in unresectable hepatocellular carcinoma[J]. World J Gastroenterol,2005,11(17):2637-2642.
|
| 21 |
Elia C, Venon WD, Stradella D, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in cirrhosis: influence on portal hypertension[J]. European Journal of Gastroenterology & Hepatology,2011,23(7):573-577.
|
| 22 |
Miyayama S, Matsui O, Yamashiro M, et al. Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil[J]. J Vasc Interv Radiol,2007,18(3):365-376.
|
| 23 |
Poon RT, Ng IO, Lau C, et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study[J]. Ann Surg,2001,233(2):227-235.
|
| 24 |
Liang B, Zheng CS, Feng GS, et al. Correlation of hypoxia-inducible factor 1alpha with angiogenesis in liver tumors after transcatheter arterial embolization in an animal model[J]. Cardiovascular & Interventional Radiology,2010,33(4):806-812.
|
| 25 |
Copple BL. Hypoxia stimulates hepatocyte epithelial to mesenchymal transition by hypoxia-inducible factor and transforming growth factor-beta-dependent mechanisms[J]. Liver Int,2010,30(5):669-682.
|
| 26 |
Tsai CC, Chen YJ, Yew TL, et al. Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST[J]. Blood,2011,117(2):459-469.
|
| 27 |
Malagari K, Pomoni M, Moschouris H, et al. Chemoembolization of hepatocellular carcinoma with HepaSphere 30-60 mum. Safety and efficacy study[J]. Cardiovascular & Interventional Radiology,2014,37(1):165-175.
|
| 28 |
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med,2008,359(4):378-390.
|
| 29 |
Jinushi M, Dranoff G. Triggering tumor immunity through angiogenesis targeting[J]. Clin Cancer Res,2007,13(13):3762-3764.
|
| 30 |
Sung PS, Bae SH, Jang JW, et al. Differences in the patterns and outcomes of enhanced viral replication between hepatitis C virus and hepatitis B virus in patients with hepatocellular carcinoma during transarterial chemolipiodolization[J]. Korean J Hepatol,2011,17(4):299-306.
|
| 31 |
Jang JW, Bae SH, Choi JY, et al. A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management[J]. Cancer Chemotherapy & Pharmacology,2007,59(1):9-15.
|
| 32 |
Pinato DJ, Sharma R. An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma[J]. Translational Research: The Journal of Laboratory & Clinical Medicine,2012,160(2):146-152.
|
| 33 |
Song BC, Chung YH, Kim JA, et al. Association between insulin-like growth factor-2 and metastases after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: a prospective study[J]. Cancer,2001,91(12):2386-2393.
|
| 34 |
Wang GZ, Fang ZT, Zhang W, et al. Increased metastatic potential of residual carcinoma after transarterial embolization in rat with McA-RH7777 hepatoma[J]. Oncol Rep,2014,31(1):95-102.
|
| 35 |
Ding JM, Jing X, Liu JB, et.al. Comparison of two different thermal techniques for the treatment ofhepatocellular carcinoma. Eur J Radiol, 2013,82(9):1379-1384.
|
| 36 |
Zhou Y, Zhao Y, Li B, et al. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol, 2010, 10:78.
|
| 37 |
Liu HC, Er-Bo Shan, Zhou L, et al. Combination of percutaneous radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: observation of clinical effects[J]. Chin J Cancer Res, 2014,26(4):471-477.
|
| 38 |
Yang W, Chen MH, Wang MQ, et al. Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment. Hepatol Res, 2009,39(3):231-240.
|